Alvotech signs licensing, commercialization deal with Lotus Pharma for Imfinzi, Hemlibra biosimilars in US, Asia

• Alvotech struck a licensing and commercialization deal with Lotus Pharmaceutical for two U.S. biosimilar candidates, AVT34 and AVT87.
• Semi-exclusive U.S. structure lets Alvotech commercialize alongside Lotus; Lotus will sell via its U.S. unit Alvogen.
• Lotus received exclusive commercialization rights in selected Asian markets; Alvotech will supply product and lead development.
• Agreement value to Alvotech totals up to USD 150 million in upfront and milestone payments, plus ongoing supply revenue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alvotech SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608210900OMX_____CNEWS_EN_GNW1001258722_en) on August 21, 2026, and is solely responsible for the information contained therein.